Biogen Inc.BIIB

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · biogen.com

Biogen Inc. is a global biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and delivering therapies for neurological, specialized immunology, and rare diseases. The company's marketed portfolio includes treatments for multiple sclerosis (TECFIDERA, TYSABRI, AVONEX), spinal muscular atrophy (SPINRAZA), Alzheimer's disease (LEQEMBI, co-commercialized with Eisai), Friedreich's Ataxia (SKYCLARYS), and ALS (QALSODY).

Key ratios

Operating cash flow growth

36.0%TTM

2025 -23.3%2024 85.9%2023 11.8%

EPS growth

-46.1%TTM

2025 -21.4%2024 40.3%2023 -61.8%

FCF / Sales

20.7%TTM

2025 20.7%2024 28.1%2023 12.9%

Net margin

8.3%TTM

2025 13.1%2024 16.9%2023 11.8%

ROA

5.2%TTM

2025 6.2%2024 6.0%2023 4.6%

ROE

4.6%TTM

2025 7.4%2024 10.4%2023 8.2%

Revenue growth

2.2%2025

2024 -1.6%2023 -3.3%

Recent news

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease 2026-09-16 · GlobeNewswire Stoke Therapeutics and Biogen Present Long-Term Clinical Data Supporting Disease-Modifying Potential of Zorevunersen for Dravet Syndrome 2026-09-03 · GlobeNewswire LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China 2026-09-03 · GlobeNewswire Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen 2026-09-01 · GlobeNewswire LEQEMBI IQLIK Autoinjector for Early Alzheimer's Disease Now Available in the U.S. 2026-08-24 · GlobeNewswire Biogen Completes Acquisition of RayThera Inc. 2026-08-06 · GlobeNewswire Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. 2026-06-17 · GlobeNewswire Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy 2026-06-04 · GlobeNewswire

Track BIIB in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer